Journal article

Performance of serum lipocalin 2 as a diagnostic marker for colorectal cancer

Kim YC Fung, Ilka Priebe, Leanne Purins, Bruce Tabor, Gemma V Brierley, Trevor Lockett, Edouard Nice, Peter Gibbs, Jeannie Tie, Paul McMurrick, James Moore, Andrew Ruszkiewicz, Antony Burgess, Leah J Cosgrove

Cancer Biomarkers | IOS PRESS | Published : 2013

Abstract

BACKGROUND: Lipocalin 2 has been implicated in colorectal tumorigenesis but its usefulness as a diagnostic marker for the disease has previously never been determined. METHODS: We have used ELISA immunoassay to measure the level of serum lipocalin 2 in a cohort consisting of colorectal cancer patients (n=196) and age/gender matched controls (n=99). RESULTS: The median concentration of lipocalin 2 was found to be significantly higher (p< 0.0001) in the patient group (105.9 ng/mL, range 10.8-444.7 ng/mL) when compared to the control subjects (86.4 ng/mL, range 17.1-190.0 ng/mL). Additionally, no significant difference was observed between disease stage (Dukes' or T stage) in the patient cohort..

View full abstract